Antiemetic Drugs Strategic Research Report 2024-2030: Pharmacogenomics and Personalized Medicine Shape the Future of Developments, Rising Cancer Rates and Chemotherapy Demand Fuel Expansion
27. August 2024 06:04 ET
|
Research and Markets
Dublin, Aug. 27, 2024 (GLOBE NEWSWIRE) -- The "Antiemetic Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Antiemetic Drugs...
The World Market for Antiemetics to 2030: Featuring Profiles of Abbott Labs, Benuvia Therapeutics, Cipla, Dr. Reddy's Labs, Eisai, and More
17. April 2024 10:55 ET
|
Research and Markets
Dublin, April 17, 2024 (GLOBE NEWSWIRE) -- The "Antiemetic Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The global...
10 Year Forecasts for the Postoperative Nausea and Vomiting (PONV) Market
06. November 2020 07:28 ET
|
Research and Markets
Dublin, Nov. 06, 2020 (GLOBE NEWSWIRE) -- The "Postoperative nausea and vomiting (PONV) - Market Insights, Epidemiology, and Market Forecast - 2028" drug pipelines has been added to...
RedHill Biopharma Publishes Positive IBS-D Phase 2 Study Data in The American Journal of Gastroenterology
28. Juli 2020 09:35 ET
|
RedHill Biopharma Ltd.
Publication of the Phase 2 U.S. study data show that RHB-102 (Bekinda®) 12mg delivers a clinically meaningful improvement in overall stool consistency response versus placebo in patients with...
Midatech Completes Acquisition of Zuplenz®
30. Dezember 2015 02:00 ET
|
Midatech Pharma PLC
OXFORDSHIRE, United Kingdom, Dec. 30, 2015 (GLOBE NEWSWIRE) -- Midatech Pharma (“Midatech” or the “Company” or the “Group”) (AIM:MTPH) (Nasdaq:MTP), the international specialty pharmaceutical...
Positive Bioavailability Studies of RedHill's BEKINDA(TM) to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Meeting
02. März 2015 07:00 ET
|
RedHill Biopharma Ltd.
The results from two positive bioavailability studies, previously reported by the Company, demonstrate the safety and tolerability of BEKINDA™ and support the European marketing application...
RedHill Biopharma Announces Closing of Public Offering of Its American Depository Shares
13. Februar 2015 10:18 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel, Feb. 13, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
RedHill Biopharma Reports Successful RHB-102 Bioavailability Clinical Trial and Planned Submission of European Marketing Application in Q3/2014
30. April 2014 07:00 ET
|
RedHill Biopharma Ltd.
RedHill received positive results from a comparative bioavailability clinical trial which included 20 healthy volunteers
In light of the positive results, and subject to regulatory...